Imagine selling a medical device to a hospital. You have the address, a promising clinical argument and a list of physicians. Then comes the awkward discovery: the person using the device may work for a group owned by a health system whose purchasing decisions happen somewhere else. The list was accurate. Your picture of the buyer was incomplete.
That gap is Definitive Healthcare’s business. It connects information about organizations, clinicians, medical activity and scientific influence so customers can work out where an opportunity lives. Its product is a more useful picture of the business around medicine, assembled from records that rarely arrive neatly connected.
- The job: connect healthcare participants, activity and buying relationships.
- The buyer: drugmakers, device firms, providers and businesses selling into healthcare.
- The test: turn better targeting into results worth renewing a subscription for.
A directory with the relationships left in
Jason Krantz founded the company in 2011. He had previously built Infinata, a pharmaceutical information business sold to Pearson. Definitive Healthcare extended that information-business instinct across the healthcare market: identify the participants, connect their relationships and make the result usable by someone with a commercial decision to make.
Consider HospitalView. Its profiles combine details such as hospital financials, executives, technology installations and affiliations. PhysicianView brings the inquiry down to professionals and their connections. Claims intelligence adds another dimension: recorded diagnoses, procedures and prescriptions. Together, these layers help distinguish a facility that sounds relevant from one whose activity fits a particular product.
Underneath sits an unglamorous problem: recognizing the same entity across different records. Definitive ID provides a common identifier to link that information. A useful map needs its roads to meet. Otherwise, a handsome dashboard can leave a sales team with disconnected answers.
The campaign that deserved to stop
BrainsWay, which sells Deep TMS systems, supplies the revealing customer example. According to a case study published by Definitive Healthcare, its representatives use diagnosis, procedure and prescription-related intelligence to identify prospects. They combine the resulting targets with Google Maps for field visits and use ZIP-code provider counts to rebalance territories.
One pilot targeted providers treating substantial numbers of older patients with mental-health conditions. It disappointed. The team redirected its effort. That detail makes the case more useful than a victory lap: data helped the company test a plausible idea and move on when the response fell short.
The same case study attributes at least ten deals, worth more than $1.3 million over eighteen months, to Definitive Healthcare leads. Those are customer-marketing claims, rather than an independently audited experiment. Still, the mechanism is concrete: qualify an audience, route the work, watch conversion and adjust. A reader can copy that sequence without copying the vendor.
- 01 Qualify
- 02 Route
- 03 Measure
- 04 Redirect
Healthcare has more buyers than you think
The customer universe stretches beyond pharmaceutical and device companies. Definitive Healthcare also serves software vendors, recruiters, consultants, financial firms and construction businesses. A builder needs to understand a hospital’s expansion opportunity; a software salesperson needs to know its installed technology. Both benefit from context a contact list cannot supply.
The product collection reflects that spread. Monocl ExpertInsight tracks scientific experts through publications, trials and other activities. Populi adds provider-market and population analysis, including referral patterns and patient outmigration. Carevoyance concentrates on medtech sales workflows. Analytics specialists and integration services help customers answer questions that a standard interface may not settle.
Definitive Healthcare competes across overlapping markets. IQVIA OneKey also connects professional and organizational reference information; Komodo Health offers claims-based commercial analytics. Definitive’s particular pitch combines organizational detail, affiliations, activity and specialist applications. A sensible comparison starts with the decision you need to make, then tests coverage and usability against that decision.
The subscription has to earn its keep
The business runs primarily on subscriptions, with pricing tailored to products, licenses and add-ons. Its public pricing page offers individual solutions and bundles. For a buyer, the meaningful cost includes the subscription, integration work and the employee time required to turn a promising signal into a qualified opportunity.
Distribution has become part of the product. Atlas data reached Snowflake Marketplace in 2023. In May 2026, the company announced HubSpot integration and expanded healthcare-professional access inside Salesforce. The practical logic is straightforward: information becomes easier to use when it appears where a team already manages its work.
Definitive itself faces the renewal test. Revenue declined from $252.2 million in 2024 to $241.5 million in 2025. Second-quarter 2026 revenue fell another 9% year over year. These numbers describe a retreat in sales, even as the business continues generating operating cash. Owning useful information does not automatically produce a growing subscription business.
The valuable map is the one that changes the next decision.THE BUYER’S TEST
A new interface. An unsettled next chapter.
In August 2026, Definitive Healthcare announced early-adopter access to a platform joining its datasets with conversational AI. The intended change is how customers ask questions across providers, claims, consumers and experts. General availability was planned for later in the year. Easier questions still depend on the underlying records being relevant and dependable.
Clay Ritchey, previously CEO of Verato, became chief executive in September. He described his task as accelerating the company’s “return to growth.” That same month, an independent board committee disclosed Advent International’s non-binding proposal to buy the shares and operating-company interests not already owned by Advent or Krantz for $1.02 apiece. The announcement described a proposal under review, with no assurance of completion.
The company describes community volunteering through DefinitiveCares alongside its technical work. Its commercial promise remains easier to judge: take a specific question, check the market coverage, validate a sample and measure the result. If missing records distort your target population, or nobody acts on the findings, a subscription will struggle to pay back. The valuable map is the one that changes the next decision.